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HLA expression in solid tumors 
 
Loss of HLA class I expression has been described in almost all epithelial tumors 
including ovarian, head and neck, breast, prostate, lung, colon and bladder cancer 
(reviewed in [1]). The frequency of HLA class I loss and/or downregulation ranges 
from 16% to 60% [1]. The highest frequency of HLA class I loss has been found in 
bladder, breast and prostate cancer, and the lowest in renal cell carcinoma. The 
percentage of HLA class I loss in head and neck sqaumous cell cancer varied 
between 30% and 70% (reviewed in [2]). In a large ovarian cancer cohort, 
approximately 65% of the cases showed HLA class I downregulation [3].  
 
Loss or downregulation of HLA class I in epithelial cancer represents an important 
cancer immune escape mechanism and is often associated with features of 
aggressive disease and a worse prognosis (ovarian, head and neck, bladder and 
breast cancer) [4-8]. SATB1 expression was positively correlated with age, depth of 
invasion, lymph node metastasis, distant metastasis and TNM stage in gastric 
cancer in a Chinese population [9] and was associated with invasive depth and 
tumor node metastasis (TNM) stage at both protein and mRNA levels in human 
rectal cancer [10]. Loss of HLA class I expression is an independent adverse 
prognostic factor in different cohorts with ovarian cancer [3, 4, 11]. 
 
Despite the clear clinical relevance of HLA class I loss, the mechanism of HLA class 
I loss in solid tumors are not known yet. Based on the positive results in cHL, we 
studied the association between HLA class I loss and the number of PML-NBs and 
SATB1 expression in Oropharyngeal squamous cell cancer and in ovarian cancer. 
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PML nuclear bodies and SATB1 are not correlated to 
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Downregulation of human leukocyte antigen (HLA) class I expression has been 
observed in a proportion of oropharyngeal squamous cell carcinoma (OpSCC) 
cases. Promyelocytic leukemia protein (PML), the main component of PML nuclear 
bodies (PML-NBs), and SATB1, partially residing within PML-NBs, organize the 
HLA class I locus into distinct loops and regulate HLA class I expression in various 
cell types. In Hodgkin lymphoma, an association is only present in Epstein barr virus 
induced cases. 
In this study, we evaluated HLA class I expression, the number of PML-NBs and 
SATB1 expression in 113 OpSCC cases on tissue microarrays. Human papilloma 
virus (HPV) was identified in the tumor cells in 18 out of 95 cases. In 77 HPV- cases, 
32 showed a positive HLA class I staining, 37 cases stained partially positive and 8 
cases showed no staining. In 18 HPV+ cases, 9 stained positive, 2 stained partially 
positive and 7 showed no staining for HLA class I. The partial positive cases were 
characterized by loss of HLA class I expression in differentiating areas of the tumor, 
similar to normal squamous epithelium. There were significantly more HLA class I 
positive or partial positive cases in HPV- than in HPV+ OpSCC (P<0.0001). The 
average number of PML-NBs scored in the least differentiated cells was highly 
variable, ranging from 0 to 13 per tumor cell nucleus in 4 um tissue sections. There 
was a significant difference in the number of PML-NBs between tonsillar and base 
of tongue squamous cell carcinoma. The average number of PML-NBs was not 
correlated with HLA class I staining in OpSCC or HPV stratified subgroups. 11% of 
the OpSCC cases were SATB1 positive. SATB1 staining was homogeneous within 
the tumor tissue and was not correlated with HLA class I staining in total as well as 
in HPV stratified cases. In conclusion, the number of PML-NBs and SATB1 are not 
associated with HLA class I expression in OpSCC.
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Introduction 
Oropharyngeal squamous cell carcinoma (OpSCC) includes squamous cell 
carcinomas of the soft palate, the base of the tongue, and the tonsils [12]. Alcohol 
and tobacco use are important risk factors and approximately 75% of all OpSCC are 
attributable to these exposures [13-15]. In addition, human papillomavirus (HPV) 
infection has been suggested as the causal agent of malignant transformation in a 
subset of OpSCC, specifically those that arise from the base of tongue and tonsil 
[12, 16, 17]. Many reports have shown that the prognosis of patients with HPV+ 
OpSCC is better than for patients with HPV-negative tumors [18]. 
 
Tonsillar squamous cell carcinoma (TSCC) is the most common tumor in the 
oropharynx accounting for 70-80% of all OpSCC. The incidence of TSCC is 
increasing and 45-93% of the cases are reported to be HPV positive suggesting a 
dominant role of HPV infection in TSCC [19, 20]. (Melchers et al. in press) Base of 
tongue cancer (BTSCC) is another common tumor of the oropharynx with a similar 
histological pattern and a worse prognosis compared with TSCC. The prevalence of 
HPV in base of tongue cancer is also increasing similar to the TSCC subtype [21].  
Downregulation of the classical HLA class I genes is frequently observed in many 
kinds of tumors, including head and neck squamous cell carcinoma (HNSCC) [1, 
22]. Low and absent HLA class I expression correlated with a worse prognosis in 
HNSCC [5, 6]. In another study, loss of HLA class I expression was an adverse 
prognostic factor specifically in HPV-negative TSCC and a favorable prognostic 
factor in HPV+ TSCC [23]. 
 
Promyelocytic leukemia protein (PML) is the main component of nuclear bodies 
(NBs) and regulates many nuclear functions such as DNA replication, transcription 
and epigenetic modifications [24]. PML has been shown to regulate HLA class I 
expression in human primary fibroblasts and to associate with the HLA locus and 
other transcriptionally active genomic regions [25, 26]. Special AT-rich sequence 
binding 1 (SATB1) regulates expression of many genes by folding chromatin into 
loop domains, tethering nuclear matrix attachment regions to the SATB1 network 
structure [27-29]. SATB1 partially resides within PML-NBs and has been shown to 
organize the HLA class I locus into distinct loops. Silencing of SATB1 in Jurkat T 
cells results in an enhanced expression of HLA-A [30]. We recently showed that the 
number of PML-NBs and SATB1 expression are associated with HLA class I 
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expression in classical Epstein barr virus (EBV) positive Hodgkin lymphoma, but not 
in EBV- cases (Liu et al in press). 
 
The expression of PML and SATB1 and their association with HLA class I have not 
been studied in OpSCC. In this study, we investigated a possible association 
between PML-NBs, SATB1 and HLA class I expression in tumor cells of patients 
with OpSCC. Because viral status may impact on this possible association, as is the 
case in classical Hodgkin lymphoma, we stratified the cases by HPV involvement.  
 
Materials and Methods 
Patients 
All diagnoses were established according to the classification guidelines of the 
World Health Organization. This study was performed according to the Code of 
Conduct for proper secondary use of human tissue in the Netherlands, as well as to 
the relevant institutional and national guidelines. Clinicopathological data was 
available for 113 OpSCC cases diagnosed in the UMCG from 1997 to 2008. The 
age at diagnosis ranged from 36 to 88 years. There were 64 cases with TSCC and 
49 cases with BTSCC. HPV status was previously assessed using a triple algorithm, 
including p16 expression, HPV-PCR and HPV-BRISH (L.J. Melchers et al. paper in 
preparation). 12 out of 61 (19.7%) TSCC and 8 out of 49 (18.4%) BTSCC were HPV 
positive. In 3 cases, HPV status was undetermined. Three representative tissue 
cores of each paraffin-embedded tissue block were used to construct tissue 
microarrays (TMA) as described previously (L.J Melchers et al. paper in press Oral 
Oncology).  
 
Immunohistochemical staining and scoring of HLA class I, PML-NBs 
and SATB1 
4µm thick paraffin sections from the TMAs were deparaffinized by xylene and 
rehydrated through a graded ethanol series. Tissue sections were incubated with 
0.3% hydrogen peroxide for 30 min to block endogenous peroxidase and antigen 
retrieval was done in 1mM Tris/EDTA solution (pH 9.0) for antigen retrieval for HLA 
class I in a microwave oven at 100°C for 15 min and for PML and SATB1 in a 
pressure cooker at 120°C for 15 min. The slides were washed with PBS, and 
incubated with the primary antibodies against HLA class I at room temperature for 1 
hour (1:200), PML (1:1600, PG-M3, Santa Cruz Biotechnology) and SATB1 (1:800, 
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14/SATB1, BD Sciences). Positive cells were visualized by 3,3’Di-Amino-Benzidine 
(DAB) staining after incubation with secondary and tertiary antibodies. Sections 
were counterstained with hematoxylin.  
 
Cases with diffuse membranous and/or cytoplasmic HLA class I tumor cell staining 
were scored as positive. Cases without any membranous or cytoplasmic staining 
were scored as negative. In a proportion of the cases only part of the tumor cells 
were HLA class I positive, these were scored as partially positive. 15 cases were 
excluded because the staining pattern for HLA class I was not clear or because of 
loss of tissue.  
 
The number of PML-NBs was scored in the tumor cells with the highest amount of 
NBs. In each case, the number of small discrete foci in the nuclei of 10 tumor cells 
per tissue core was counted to determine the average number of PML-NBs per 
tumor cell nucleus in a 4μm tissue section. We only included a case if there were at 
least 2 evaluable tissue cores and if the non-malignant background cells showed 
positive staining. 16 of 113 cases were excluded because PML-NBs were not 
countable.   
 
For SATB1 the cases were scored based on the presence of a diffuse SATB1 
staining pattern in the nucleus of the tumor cells. If there was no nuclear signal in 
the tumor cells or only a few tumor cells stained positive, we defined them as 
negative. If there were positive nuclear signals in the vast majority of the tumor cells, 
we defined them as positive. 5 out of 113 cases were not scorable for SATB1 and 
were excluded. Reactive inflammatory, vascular or stromal cells served as internal 
positive control for HLA class I, PML and SATB1.  
 
Statistical analysis 
Differences between HPV+ and HPV-, between HLA class I expression defined 
subgroups, between SATB1 negative and positive cases and between cases 
categorized into quartiles according to the number of PML-NBs were evaluated 
respectively by the Chi-square test or Fisher exact test for ordinal variables and 
Kruskal-Wallis or Mann-Whitney test for scale variables. P values less than 0.05 





HLA class I expression in relation to HPV status and patient 
characteristics 
We found three staining patterns of HLA class I in OpSCC cases. Representative 
cases with negative, partially positive and positive HLA class I staining in squamous 
tumor cells are shown in Fig 1A-C. In 77 HPV- cases, 32 showed positive staining, 
37 stained partially positive and 8 cases were negative (Table 1). In 18 HPV+ cases, 
9 stained positive, 2 stained partially positive and 7 cases stained negative for HLA 
class I. There were significantly more HLA class I positive cases in HPV- cases than 
in HPV+ cases (P<0.0001). Borderline significant differences were observed for 
tumor stage, with more HLA class I positive cases in stage T3 or T4 cases (P=0.09, 
Table 1). Age, gender, smoking history, tumor site, clinical lymph node stage, 
treatment intent, pathological stage and recurrence status were not correlated with 
HLA class I staining intensity in the total population (Table 1) nor in HPV stratified 
subgroups (data not shown).  
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Figure 1. Representative immunostaining results of HLA class I, PML-NBs and SATB1 in 
tonsillar and base-of-tongue squamous cell carcinomas. A) HLA class I negative case. B) A 
case with HLA class I partial positive staining. HLA class I staining is lost in differentiating cells, 
similar to normal, non-neoplastic squamous epithelium. C) HLA class I positive case. All tumor 
cells stain positive for HLA class I. D) OpSCC case with a low number of PML-NBs per tumor cell. 
E) OpSCC case with a high number of PML-NBs per tumor cell. F,G) A case with staining of HLA 
class I and PML-NBs in the same tissue area (consecutive slides). F) There is only positive HLA 
class I staining in the least differentiated tumor cells G) The number of PML-NBs is the highest in 
the least differentiated tumor cells. This pattern is positively correlated to the level of HLA class I 
expression. H) SATB1 negative case. I) SATB1 positive case. 
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PML and SATB1 staining in relation to HLA class I expression and 
clinical parameters in OpSCC cases 
The PML antibody showed a randomly distributed staining of discrete nuclear dots 
representing the PML-NBs. Representative cases are shown in Fig. 1D and E. We 
checked the heterogeneity of the average number of PML-NBs per tumor cell 
between different tissue cores in 20 randomly selected cases. In the majority of 
these cases, the average number of PML-NBs was fairly consistent between tissue 
cores within each case (Supplementary Fig 1). Overall, the average number of 
PML-NBs varied from 0-13 per tumor cell nucleus in 4μm thick tissue sections 
(Supplementary Table 2). In the total population, the site of the tumor was 
significantly correlated to the number of PML-NBs divided into quartiles (P=0.05, 
Table 2). There were no significant differences in the number of PML-NBs between 
HPV+ and HPV- cases (Fig 2). The number of PML-NBs were not correlated to the 
HLA class I staining in the total population as well as in HPV+ or HPV- cases (Fig 3). 
In cases with partial positive HLA class I staining, a very consistent association was 
observed between the loss of HLA class I and a decreased number of PML-NBs in 
more differentiated cells (Figure 1F, G).  
 
SATB1 staining patterns are shown in Figure 1H and 1I. 12 out of 108 cases (11.1%) 
stained positive for SATB1. In the total population SATB1 staining was not 
associated with any clinical parameter. The only suggestive correlation observed 
was between SATB1 positivity and treatment intent (P=0.09, Table 3). In HPV- 
cases, 10 out of 84 cases were SATB1 positive (12%) and a borderline significant 
difference was observed for smoking history (P=0.08, data not shown) and 
treatment intent (P=0.07, data not shown). In HPV+ cases, 2 cases stained positive 
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Figure 2. PML staining results in relation to HLA class I in OpSCC cases. HPV- cases are 
depicted in white symbols and HPV+ cases in black symbols. The average number of PML-NBs is 
not correlated with HLA class I staining intensity. It appears that there were no HPV+ cases in the 
partially positive HLA class I group, however, the two HPV+ and partially HLA class I+ cases were 
not evaluable for PML. 
 
Discussion 
The mechanisms underlying the loss of HLA class I expression in OpSCC are not 
clear. In this study, we found complete HLA class I loss in 50% of the HPV+ cases 
and in only 10% of the HPV- cases. This significant difference indicates that HLA 
class I expression is strongly associated with HPV status. Even after stratification 
for HPV status, we did not observe a correlation between the number of PML-NBs, 
SATB1 and HLA class I in OpSCC.  
 
The strong association between HPV and HLA class I downregulation in HPV+ 
cases suggests a link with HPV. Indeed, overexpression of the E7 oncoprotein of 
HPV-16 has been shown to downregulate membranous HLA class I as well as 
antigen peptide transporter 1 (TAP1) expression in a cervical cancer cell line [31]. 
This reflects an important mechanism of the virus to escape from anti-HPV immune 
responses.  
 
In this study we focused on the correlation between expression of HLA class I, the 
number of PML-NBs and the expression of SATB1. Since PML and SATB1 are 
known to regulate HLA class I transcription levels, we considered both membranous 
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staining and cytoplasmic HLA class I staining as being positive. Approximately half 
of the cases showed partial positive staining for HLA class I. In these cases clear 
tumor cell differentiation, sometimes with keratinization was seen. The smaller, least 
differentiated tumor cells were HLA class I positive and had the highest numbers of 
PML-NBs. In differentiating tumor cells both HLA class I expression and the 
numbers of PML-NBs were lower or completely absent. This pattern is similar to 
what can be observed in normal squamous epithelium in skin tissue [32-34]. 
Consistent with our observation in tumor cells, we also observed that the loss of 
HLA class I occurred together with the loss of PML-NBs in normal squamous 
epithelium (data not shown). This indicates that PML may play a role in the 
regulation HLA class I expression during the keratinization stages in both tumor 
cells and normal squamous cells.  
 
We did not find an association of PML and SATB1 expression with HLA class I 
expression in the total or HPV stratified cases. As this is the first study to explore 
this association in OpSCC, we can not compare our data to previously reported 
studies. However, in a similar approach we did find correlations in ovarian cancer 
(Chapter 6B) and EBV+ classical Hodgkin lymphoma (Chapter 4). The number of 
HPV+ OpSCC cases analyzed in this study is relatively low and expression of the 
oncogenic E7 protein may be a dominant factor affecting HLA class I expression. 
Additional cases need to be studied to definitively rule out a possible association. In 
the HPV- cases PML-NBs and SATB1 were not associated similar to the results 
obtained in EBV- cHL cases and other mechanisms need to be investigated.  
 
We found SATB1 positive tumor cells in ~10% of the OpSCC cases. In comparison 
to other solid tumors, such as breast, gastric, rectal and laryngeal cancer at 
frequencies ranging from 44% to 66%, this percentage is relatively low [9, 10, 35]. 
However, it has to be noted that there are differences in antibodies used and in 
many publications very high antibody concentrations have been applied and 
cytoplasmic SATB1 staining was also scored as being positive. We did not find any 
significant correlation between SATB1 and clinicopathological characteristics, but 
SATB1 positivity was observed more frequently in patients with adverse prognosis 
and patients receiving palliative treatment, indicating that SATB1 may be involved in 
tumor progression or differentiation in OpSCC. Elevated SATB1 expression at both 
the mRNA and protein level correlated with high clinical stages and poor 
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differentiation status in laryngeal squamous cell carcinoma [35]. Low and absent 
HLA class I expression has been correlated with a worse prognosis in head and 
neck squamous cell carcinoma [5, 6]. In contrast, in a large cohort of HPV-positive 
TSCC, a low HLA class I expression was significantly correlated to a favorable 
clinical outcome, whereas in HPV-negative TSCC, a normal HLA class I was 
correlated to a favorable clinical outcome [23].  
 
In conclusion, HLA class I is strongly associated with HPV status, but not with the 
number of PML-NBs and SATB1 expression in OpSCC or HPV stratified subgroups.  
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Table 1. Statistical analysis of the correlation of clinicopathological characteristics, 




HLA class I staining    
 negative partial positive positive p value 
  n % n % n %   
Sex        
Male 13 18.8 30 43.5 26 37.7 0.70a 
Female 6 20.7 10 34.5 13 44.8  
Age at diagnosis (yrs)        
Median 60 58 57 0.78b 
Range (40-71) (36-88) (41-85)  
Smoking history (n=83)        
No 4 33.3 2 16.7 6 50.0 0.17a 
Yes 12 16.9 31 43.7 28 39.4  
Site        
Tonsil 6 14.3 21 50.0 15 35.7 0.25a 
Base-of-tongue 13 23.2 19 33.9 24 39.8  
cT status        
1-2 10 32.3 10 32.3 19 35.5 0.09a 
3-4 9 13.4 30 44.8 28 41.8   
cN status        
0 1 5.6 8 44.4 9 50.0 0.24a 
+ 18 22.5 32 40.0 30 37.5  
Treatment intent        
Curative 16 21.6 30 40.5 28 37.8 0.58a 
Palliative 3 12.5 10 41.7 11 45.8  
pT status (n=28)        
1-2 3 18.8 4 25.0 9 56.2 0.64a 
3-4 2 16.7 5 41.7 5 41.7  
pN status (n=33)     
0 2 22.2 2 22.2 5 55.6  0.75a 
+ 6 25.0 8 33.3 10 41.7  
Recurrence         
No 14 20.3 28 40.6 27 39.1  0.94a 
Yes 5 17.2 12 41.4 12 41.4  
Hr-HPV status (n=95)        
Negative 8 10.4 37 48.1 32 41.6 <0.0001a 
Positive 9 50.0 2 11.1 7 38.9  
Average number of PML-NBs per cell         
Median 3.7 4.3 5.0 0.27b 
Range (0.3-9.1) (0.4-13.2) (0-12)  
SATB1 staining intensity        
Negative 16 18.2 37 42.0 35 39.8 0.62a 
Positive 3 30.0 3 30.0 4 40.0  
a Chi-square test, b Kruskal-Wallis test  
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Table 2. Statistical analysis of the correlation of clinicopathological characteristics 
with PML-NBs quartiles in OpSCC (n=97, total population).  
 
 
The number of PML-NBs per tumor cell nucleus in 
quartile p value 
 0-25% 26-50% 51-75% 76-100% 
 n % n % n % n % 
Sex          
Male 17 25.8 14 21.2 16 24.2 19 28.8 0.60a 
Female 7 22.6 10 32.3 8 25.8 6 19.4  
Age at diagnosis (yrs)          
Median 54 56 57 59 0.67b 
Range (40-88) (45-87) (36-88) (36-86)  
Smoking history (n=80)          
No 1 9.1 3 27.3 4 36.4 3 27.3 0.60a 
Yes 19 27.5 16 23.2 17 24.6 17 24.6  
Site          
Tonsil 17 32.1 8 15.1 12 22.6 16 30.2 0.05a 
Base-of-tongue 7 15.9 16 36.4 12 27.3 9 20.5  
cT status          
1-2 9 25.7 8 22.9 11 31.4 7 20.0 0.62a 
3-4 15 24.2 16 25.8 13 21.0 18 29.0  
cN status          
0 5 27.8 6 33.3 3 16.7 2 22.2 0.70a 
+ 19 24.1 18 22.8 21 26.6 21 26.6  
Treatment intent          
Curative 19 25.3 16 21.3 22 29.3 18 24.0 0.19a 
Palliative 5 22.7 8 36.4 2 9.1 7 31.8  
pT status (n=23)          
1-2 4 30.8 4 30.8 3 23.1 2 15.4 0.31a 
3-4 1 10.0 2 20.0 2 20.0 5 50.0  
pN status (n=29)          
0 1 12.5 3 37.5 1 12.5 3 37.5 0.58a 
+ 5 23.8 6 28.6 6 28.6 4 19.0  
Recurrence          
No 17 25.8 17 25.8 15 22.7 17 25.8 0.92a 
Yes 7 22.6 7 22.6 9 29.0 8 25.8  
HLA class I staining 
intensity (n=87) 
         
Negative 5 29.4 5 29.4 4 23.5 3 17.6 0.86a 
Partial positive 9 25.7 8 22.9 7 20.0 11 31.4  
Positive  6 17.1 8 22.9 10 28.6 11 31.4  
 
a Chi-square test, b Kruskal-Wallis test  
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Table 3. Statistical analyses of the correlation of clinicopathological characteristics 
with SATB staining patterns in OpSCC (n=108, total population). 
  
 
SATB1 staining staining   
 negative  positive p value 
  n % n %   
Sex      
Male 66 89.2 8 10.8 0.88a 
Female 30 88.2 4 11.8  
Age at diagnosis (yrs)      
Median 57 58 0.12b 
Range (36-87) (45-88)  
Smoking history (n=91)      
No 11 84.6 2 15.4 0.47a 
Yes 71 91.0 7 9.0  
Site      
Tonsil 43 87.8 6 12.2 0.77a 
Base-of-tongue 53 89.8 6 10.2  
cT status      
1-2 31 83.8 6 16.2 0.22a 
3-4 65 91.5 6 8.5  
cN status      
0 18 90.0 2 10.0 0.86a 
+ 78 88.6 10 11.4  
Treatment intent      
Curative 77 91.7 7 8.3 0.09a 
Palliative 19 79.2 5 20.8  
pT status (n=29)      
1-2 14 87.5 2 12.5 0.19c 
3-4 13 100.0 0 0.0  
pN status (n=36)     
0 9 100.0 0 0.0 0.56c 
+ 26 96.3 1 3.7  
Recurrence      
No 66 88.0 9 12.0 0.66a 
Yes 30 90.9 3 9.1  
 
a Chi-square test; b Mann Whitney test; c Fisher’s exact test 
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Supplementary Table 1. Comparison of clinicopathological characteristics between 
HPV+ cases and HPV- cases n OpSCC (n=110). 
  
 
HPV status*  
 negative  positive p value 
  n % n %   
Sex      
Male 57 78.1 16 21.9 0.29a 
Female 32 86.5 5 13.5  
Age at diagnosis (yrs)      
Median 60 57 0.49b 
Range (40-71) (36-88)  
Smoking history (n=94)      
No 8 57.1 6 42.9 0.02a 
Yes 67 83.8 13 16.2  
Site (n=110)      
Tonsil 49 80.3 12 19.7 0.86a 
Base-of-tongue 40 81.6 9 18.4  
cT status (n=110)      
1-2 23 65.7 12 34.3 0.01a 
3-4 66 88.0 9 12.0   
cN status (n=110)      
0 18 85.7 3 14.3 0.53a 
+ 71 79.8 18 19.1  
Treatment intent (n=110)      
Curative 67 77.9 19 22.1 0.13a 
Palliative 22 91.7 2 8.3  
pT status (n=33)      
1-2 12 70.6 5 29.4 0.03a 
3-4 16 100.0 0 0.0  
pN status (n=41)    
0 10 90.9 1 9.1  0.23a 
+ 22 73.3 8 26.7  
Recurrence (n=110)      
No 63 79.7 16 20.3  0.62a 
Yes 26 83.9 5 16.1  
 


































Supplementary Figure 1. The average number of PML-NBs in different cores per case in 20 
randomly selected cases. Ten tumor cells per core were counted to calculate the average number 
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Downregulation of human leukocyte antigen (HLA) class I expression in ovarian 
cancer is considered to be a mechanism to escape from effective anti-tumor 
immune responses. Promyelocytic leukemia protein (PML), a global chromatin 
organizing protein, is the main component of PML nuclear bodies (PML-NBs). PML 
has been shown to regulate HLA class I expression in Jurkat cells and possibly in 
EBV+ cHL. In this study, we evaluated HLA class I expression and the number of 
PML-NBs in 85 ovarian cancer cases on tissue microarrays. In 23 cases, HLA class 
I negative staining was negative, whereas 33 cases showed a partial positive 
staining and 29 cases showed a normal HLA class I staining. The average number 
of PML-NBs was highly variable between cases, ranging from 0 to 14 per tumor cell 
nucleus in 4 um tissue sections. The average number of PML-NBs was positively 
correlated to HLA class I expression (P<0.001). In conclusion, the number of 
PML-NBs is associated with HLA class I expression levels in ovarian cancer. 
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Introduction 
Ovarian Cancer is the sixth most common cancer world-wide among women in 
developed countries and the most lethal of all gynecologic malignancies with a 
5-year survival of less than 30% [36]. Downregulation of molecules involved in the 
antigen presentation pathway has been found in different cohorts of ovarian cancer. 
Loss of HLA class I expression is an independent prognostic factor for poor 
outcome [3, 4, 11].  
 
Promyelocytic leukemia protein (PML) is the main component of nuclear bodies 
(NBs). PML-NBs are discrete nuclear foci of 0.2 to 1.0µm that are present in the 
nuclei of most mammalian cells. PML-NBs are dynamic nuclear matrix-associated 
domains that recruit a variety of proteins and regulate many nuclear functions such 
as DNA replication, transcription and epigenetic modifications [24]. There are 5 to 
30 PML-NBs per nucleus depending on the cell type, cell cycle phase and 
differentiation stage [37]. PML has been shown to associate with the HLA locus and 
regulate HLA class I expression [25, 26]. PML induces the expression of HLA class I 
heavy chain and β2-microglobulin at the level of transcription in lung cancer cell 
lines [38]. Downregulation of PML results in a reduced HLA-A (classical antigen 
presenting HLA class I) expression in Jurkat cells [30]. In EBV+ classical Hodgkin 
lymphoma cases, we previously found that the number of PML-NBs is positively 
associated with the level of HLA class I expression (Y Liu et al. in press). 
 
The expression of PML has not been studied before in ovarian cancer. The 
mechanisms underlying the loss of HLA class I in ovarian cancer are not clear. In 
this study, we investigated a possible association between PML-NBs and HLA class 
I expression in tumor cells of ovarian cancer patients. 
 
Materials and Methods 
Patients 
Patients were treated with primary debulking surgery according to standard 
treatment protocols. All diagnoses were established according to the classification 
guidelines of the World Health Organization. The protocol for this study was 
approved by the medical ethics board of the University Medical Center Groningen. 
85 cases diagnosed between 1995 and 2003 were selected for this study. The age 
at diagnosis ranged from 25 to 82 years. Four representative tissue cores of each 
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paraffin-embedded tissue block were used to construct tissue microarrays (TMA) as 
described in a previous study [3]. Four of these TMAs were used in the current 
study. Membrane staining of HLA class I was scored previously by staining with the 
HC10 antibody. Scoring was done based on the intensity and percentage of positive 
tumor cells [3]. Briefly, the intensity of staining was scored as 0, 1, 2, or 3, indicating 
absent, weak, positive, or strong positive expression, respectively. The percentage 
of positive cells was scored as 0 for 0%; 1 for 1–5%; 2 for 5–25%; 3 for 25–50%; 4 
for 50–75% and 5 for 75–100%. The sum of both scores was used to identify three 
categories of expression: negative (0–2), partial positive (3-6) and normal 
expression (total score 7–8). Immunohistochemical staining demonstrated positive 
staining of HLA class I in tumor-infiltrating inflammatory cells, which served as an 
internal positive control. Cases with minimally two cores with a minimum of 20% 
tumor tissue were considered to be evaluable. 
 
Immunohistochemical staining and scoring of PML-NBs 
4-µm thick paraffin sections from the TMAs were deparaffinized by xylene and 
rehydrated through a graded ethanol series. Tissue sections were incubated with 
0.3% hydrogen peroxide for 30 min to block endogenous peroxidase and antigen 
retrieval was done in 1mM Tris/EDTA solution (pH 9.0) for antigen retrieval in a 
pressure cooker at 120°C for 15 min. The slides were washed with PBS, and 
incubated with the primary antibody against PML (PG-M3, Santa Cruz 
Biotechnology) overnight at 4°C. Positive cells were visualized by 
3,3’Di-Amino-Benzidine (DAB) staining after incubation with secondary and tertiary 
antibodies. Sections were counterstained with hematoxylin. The number of 
PML-NBs was scored by YL and AD, without knowledge of the HLA class I 
expression pattern. We counted the number of small discrete foci in the nuclei of 10 
tumor cells per tissue core to determine the average number of PML-NBs per tumor 
cell nucleus per 4 μm. We only included a case if there were at least 2 evaluable 
tissue cores and if non-malignant background cells showed positive staining. 20 
random cases were selected to show consistency of the counting results within 
individual cases. 
 
In three random cases with 0 to 5 PML-NBs per nucleus, three random cases with 6 
to 10 PML-NBs per nucleus and three random cases with >10 PML-NBs per 
nucleus, we measured the nuclear surface area of 10 individual tumor cells in each 
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case (90 tumor cells in total) by Aperio ImageScope software v11.1 after digitally 
capturing the slides (Aperio Scanscope) and correlated tumor nucleus size to the 
number of PML-NBs. 
 
Statistical analysis 
Correlation between the number of PML-NBs in tumor nuclei and the HLA class I 
membrane staining intensity was evaluated by Kruskal-Wallis test and by the 
post-hoc Dunn’s multiple comparison test. Linear regression analysis was used to 
evaluate the correlation between the number of PML-NBs per nucleus and the 
nuclear surface area. P values less than 0.05 were considered to be significant. 
SPSS 20.0 was used for the analyses. 
 
Results 
PML staining in relation to tumor nucleus size in ovarian cancer cases 
The PML antibody stained PML-NBs as randomly distributed discrete nuclear dots. 
Representative cases are shown in Fig. 1. We first checked the heterogeneity of the 
average number of PML-NBs per tumor cell between different tissue cores in 20 
randomly selected cases. In the majority of these cases, the average number of 
PML-NBs was fairly consistent between tissue cores within each case 
(Supplementary Fig 1). The average number of PML-NBs varied from 0-14 per 
tumor cell nucleus per 4μm tissue section (Supplementary Fig 2). There were 4 to 5 
PML-NBs in the tumor infiltrating lymphocytes and we also saw strongly positive 
stromal cells with numerous PML-NBs in the nucleus.  
 
Since the size of the tumor cell nucleus is variable, we explored if the number of 
PML-NBs counted in a 4µm tissue section was related to the size of the nucleus. 
We correlated the number of PML-NBs to the nuclear surface area in 10 individual 
tumor cells per case in 9 different cases (3 cases with average 0-5 NBs per cell, 3 
cases with 5-10 NBs per cell and 3 cases with >10 PML-NBs). The surface area of 
tumor cell nuclei in 4μm tissue sections ranged from 35 to 224 μm2 and the number 
of PML-NBs per nucleus ranged from 0 to 19 with sporadic tumor cells showing 
even more PML-NBs. No significant correlation was observed between the size of 
the tumor nucleus and the number PML-NBs (p=0.09, r2= 0.03, Suppl. Figure 2). 
Considering the tumor cell nuclei as spheres, we estimate that there are close to 0 




Figure 1. Representative immunostaining results of HLA class I and PML-NBs in ovarian 
carcinoma. A) ovarian carcinoma case with a low number of PML-NBs per tumor cell. B) ovarian 
carcinoma case with a high number of PML-NBs per tumor cell. C) HLA class I negative case. D) 
HLA class I partially positive case. Some of the tumor cells are HLA class I membranous positive, 
whereas other tumor cells are negative. E) HLA class I positive case. All tumor cells stain positive 
for HLA class I. 
 
PML staining in relation to HLA class I expression in ovarian cancer 
cases 
We checked the correlation between HLA class I staining and the average number 
of PML-NBs per case. Representative cases with negative, partially positive and 
normal HLA class I staining in tumor cells are shown in Fig. 1C-E. 29 cases showed 
a normal staining intensity of HLA class I in the tumor cells, 33 cases were scored 
as partially positive showing a positive staining in part of the tumor cells and 23 
cases were scored as negative for HLA class I.  
 
The number of PML-NBs per tumor cell increased, with the lowest number in the 
HLA class I negative group, an intermediate number in the HLA class I partial 
positive group and the highest number in the HLA class I normal group (Fig. 2). 
Posthoc test showed statistically significant differences in the number of PML-NBs 
between HLA class I negative and normal or between HLA class I partially positive 
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and normal groups. The number of PML-NBs showed no significant differences 
between the HLA class I negative and partial positive groups.  
 







































Figure 2. PML staining results in relation to HLA class I in 85 ovarian cancer patients. The 
number of PML-NBs per tumor cell per 4μm significantly differed between HLA class I negative, 
partial positive and normal staining cases (P=0.0003, Kruskal-Wallis test). The number of 
PML-NBs significantly differed between HLA class I negative and normal (P<0.001) and between 




In this study, we found a positive correlation between the number of PML-NBs and 
HLA class I staining intensity in ovarian cancer cases. This is consistent with the 
results of a previous study showing that inhibition of PML-III and PML-V isoforms 
resulted in a downregulation of the expression of a distinct set of HLA class I genes 
in Jurkat cells [30] and our previous findings in EBV+ cHL (Liu et al in press). The 
results indicate that PML may play a role in the regulation of HLA class I expression 
in ovarian cancer. As downregulation of HLA class I has been correlated with a 
worse prognosis in ovarian cancer [3, 4, 11], it is of interest to determine if PML also 
is an independent prognostic factor in ovarian cancer.  
 
We found a highly variable number of PML-NBs in ovarian cancer. In a previous 
study, PML was downregulated in cancers of various histological origins, such as 
prostate, breast, CNS, colon, lung and gastric cancer [39]. Its loss was associated 
with tumor grade and progression in some histological subtypes [39]. The 
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progression from prostate intraepithelial neoplasia to invasive carcinoma was 
associated with total PML loss in prostate cancer [39]. Complete PML loss was 
associated with lymph node metastasis in breast cancer and also correlated with 
higher grade in CNS tumors [39]. Other studies subsequently evaluated PML as a 
prognostic factor and found that downregulation of PML was associated with poor 
survival in ampullary cancer [40] as well as in gallbladder cancer [41]. In gastric 
cancer, downregulation of PML was associated with an increased incidence of 
lymphatic invasion, development of higher TNM staging and unfavorable prognosis 
[42]. In ovarian cancer the prognostic value of PML-NBs has not been studied yet 
and our patient cohort was too small to reliably establish a potential prognostic 
effect.  
 
In conclusion, we found a positive correlation between the number of PML-NBs and 
HLA class I expression in ovarian cancer.  
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Supplementary Figure 1. The average number of PML-NBs in different cores per case in 20 
randomly selected cases. Ten tumor cells per core were counted to calculate the average number 
of PML-NBs per core.    





















Supplementary Figure 2. Correlation of the number of PML-NBs with nuclear size in 90 tumor cells 
from 9 random different cases (3 cases with an average of 0-5 NBs per cell, 3 cases with 5-10 NBs 
per cell and 3 cases with >10 PML-NBs). There is no correlation between the number of PML-NBs 
and size of the tumor cell nucleus. 
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Supplementary Table 1. HLA class I and PML staining results for all ovarian cancer 
patients. 
Patient number Age at diagnosis 
HLA class I 
staining 
The average number of 
PML-NBs per tumor cell 
1 78 - 0 
2 60 - 0 
3 51 - 1 
4 77 - 1 
5 53 - 1 
6 42 - 1 
7 37 - 2 
8 61 - 2 
9 56 - 2 
10 33 - 3 
11 68 - 3 
12 71 - 4 
13 48 - 4 
14 74 - 4 
15 57 - 4 
16 53 - 5 
17 47 - 5 
18 58 - 6 
19 48 - 7 
20 67 - 7 
21 81 - 9 
22 66 - 9 
23 45 - 12 
24 68 +/- 2 
25 73 +/- 2 
26 67 +/- 2 
27 61 +/- 2 
28 69 +/- 3 
29 63 +/- 3 
30 47 +/- 3 
31 64 +/- 3 
32 25 +/- 3 
33 39 +/- 3 
34 76 +/- 3 
35 71 +/- 3 
36 66 +/- 4 
37 76 +/- 4 
38 63 +/- 4 
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39 49 +/- 4 
40 55 +/- 4 
41 71 +/- 4 
42 76 +/- 4 
43 51 +/- 4 
44 71 +/- 5 
45 78 +/- 5 
46 50 +/- 5 
47 60 +/- 6 
48 68 +/- 6 
49 80 +/- 6 
50 60 +/- 7 
51 43 +/- 7 
52 48 +/- 7 
53 68 +/- 8 
54 63 +/- 10 
55 79 +/- 11 
56 82 +/- 14 
57 55 + 1 
58 66 + 2 
59 44 + 3 
60 40 + 3 
61 52 + 4 
62 60 + 4 
63 72 + 5 
64 46 + 5 
65 34 + 5 
66 60 + 6 
67 42 + 6 
68 48 + 6 
69 58 + 6 
70 43 + 7 
71 43 + 7 
72 56 + 8 
73 64 + 8 
74 80 + 8 
75 42 + 9 
76 52 + 9 
77 69 + 9 
78 71 + 9 
79 46 + 9 
80 72 + 10 
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81 43 + 11 
82 58 + 11 
83 62 + 12 
84 67 + 12 
85 67 + 12 
-, negative; +/- partially positive; +, normal. 
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